SOBI003 receives EC orphan designation to treat mucopolysaccharidosis type IIIA
Swedish Orphan Biovitrum AB (Sobi) has secured orphan designation from the European Commission (EC) for its development product candidate SOBI003, a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).
